Bristol Myers Squibb Partners with Evinova to Deploy AI-Driven Clinical Trial Optimization Platform
核心洞察
Bristol Myers Squibb (搜索) has signed an agreement with Evinova (搜索) to deploy AI-native clinical development platform across its global portfolio to optimize trial design and accelerate drug development timelines.
The collaboration will utilize Evinova (搜索)'s Cost Optimizer module within Study Designer to harness artificial intelligence for improved decision-making and identification of productivity opportunities in clinical trials.
Evinova (搜索)'s AI platform has demonstrated proven outcomes including up to 60% improvement in patient experience, 6-month acceleration in trial delivery, and 32% reduction in costs according to results published in Nature Medicine.
Bristol Myers Squibb (搜索) has entered into a strategic agreement with Evinova (搜索) to optimize clinical trials using artificial intelligence, marking a significant step toward transforming pharmaceutical drug development through advanced digital technologies. The collaboration will deploy Evinova's Cost Optimizer module across Bristol Myers Squibb's global portfolio to improve trial design efficiency and accelerate innovation timelines.
AI-Native Platform Deployment
Under the agreement, Bristol Myers Squibb (搜索) will implement Evinova (搜索)'s Study Designer platform, which harnesses advanced artificial intelligence to enhance insight-driven decision making and identify productivity opportunities. The AI-native platform is designed to unlock more efficient trial designs that accelerate innovation while improving experiences for both clinical sites and patients.
"Drug development is changing rapidly, and life science companies need partners who bring both AI leadership and clinical development expertise to successfully drive transformation," said Cristina Duran, President of Evinova (搜索). "Evinova, founded by pharma for pharma, combines AI innovation with deep industry insight to reimagine clinical development."
Addressing Industry Challenges
The collaboration addresses longstanding inefficiencies in pharmaceutical development that have plagued the industry for years. Cristian Massacesi, MD, EVP, Chief Medical Officer & Head of Development at Bristol Myers Squibb (搜索), emphasized the urgent need for transformation in clinical development.
"Transforming clinical development is not just an opportunity; it is an urgent necessity," Massacesi stated. "For years, developing medicines has taken too long, cost too much money, and mostly resulted in failure. Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come."
Platform Capabilities and Proven Outcomes
Evinova (搜索)'s AI-native platform for clinical development utilizes agentic AI to enhance study design and streamline processes through collaboration while enabling seamless digital data flow in USDM standards. The platform incorporates robust controls and safeguards to ensure responsible AI integration into clinical development processes.
The end-to-end platform is globally scaled and brings together functionality that has delivered hundreds of millions of dollars in multi-year savings for customers. Evinova (搜索)'s solutions have demonstrated measurable improvements across multiple metrics, with proven outcomes published in Nature Medicine showing up to 60% improvement in patient experience, 6-month acceleration in trial delivery, and 32% reduction in costs.
Comprehensive Trial Solutions
Beyond trial optimization, Evinova (搜索)'s Unified Trial Solution integrates critical study elements into an improved, connected trial experience for sponsors, sites, and patients. The solution seamlessly integrates eCOA with telehealth and connected devices for remote patient monitoring (RPM) for toxicity management, removing friction points and enabling robust data collection for novel endpoints and innovative trial designs.
The platform's human-centered approach to product development incorporates input from patients and trial site teams, evidenced by industry-leading eCOA compliance metrics and user engagement scores. Solutions on Evinova (搜索)'s AI platform are proven to accelerate timelines, reduce costs, improve data quality, enhance patient experiences, reduce the duration of adverse events, and ultimately achieve better outcomes.
Strategic Industry Impact
The partnership represents a broader industry shift toward AI-enabled clinical development, with Evinova (搜索) positioning itself as a separate health tech company within the AstraZeneca group. The collaboration aims to redefine clinical development to be faster, more efficient, and truly patient-centric, with potential implications for accelerating breakthrough therapies to market.